WO2009100283A2 - Tooth sealant - Google Patents

Tooth sealant Download PDF

Info

Publication number
WO2009100283A2
WO2009100283A2 PCT/US2009/033312 US2009033312W WO2009100283A2 WO 2009100283 A2 WO2009100283 A2 WO 2009100283A2 US 2009033312 W US2009033312 W US 2009033312W WO 2009100283 A2 WO2009100283 A2 WO 2009100283A2
Authority
WO
WIPO (PCT)
Prior art keywords
fluoride
composition
recited
dental
sealant
Prior art date
Application number
PCT/US2009/033312
Other languages
French (fr)
Other versions
WO2009100283A3 (en
Inventor
Michael Prencipe
Rajnish Kohli
Richard Robinson
Richard Sullivan
Original Assignee
Colgate-Palmolive Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US12/866,766 priority Critical patent/US10391038B2/en
Priority to EP09708758.9A priority patent/EP2249764B1/en
Priority to JP2010544489A priority patent/JP2011510095A/en
Priority to BRPI0907103A priority patent/BRPI0907103A2/en
Priority to CA2711262A priority patent/CA2711262C/en
Priority to CN2009801045327A priority patent/CN101938970A/en
Application filed by Colgate-Palmolive Company filed Critical Colgate-Palmolive Company
Priority to RU2010137322/15A priority patent/RU2493812C2/en
Priority to AU2009212339A priority patent/AU2009212339B2/en
Priority to MX2010007738A priority patent/MX2010007738A/en
Publication of WO2009100283A2 publication Critical patent/WO2009100283A2/en
Publication of WO2009100283A3 publication Critical patent/WO2009100283A3/en
Priority to ZA2010/03694A priority patent/ZA201003694B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0216Solid or semisolid forms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00Preparations for dentistry
    • A61K6/20Protective coatings for natural or artificial teeth, e.g. sealings, dye coatings or varnish
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/20Halogens; Compounds thereof
    • A61K8/21Fluorides; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A61Q11/02Preparations for deodorising, bleaching or disinfecting dentures
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/22Gas releasing
    • A61K2800/222Effervescent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41Particular ingredients further characterized by their size
    • A61K2800/412Microsized, i.e. having sizes between 0.1 and 100 microns

Definitions

  • the present invention relates to tooth sealant compositions comprising a basic amino acid in free or salt form that may be used to help prevent demineralization of teeth, alleviate pain and/or sensitivity of a patient's teeth, and provide other benefits.
  • Sealants may include polymeric coatings, varnishes and foams to coat the teeth and/or dental device for extended periods.
  • Dental caries consist of demineralization of a tooth caused by bacteria. In the early stages of caries a white spot develops on the tooth and if the disease is not halted and reversed, the enamel surface breaks down to form a lesion. This can then lead to decay and eventually, a fractured tooth. It is well known that development of dental caries may be reduced by means of various factors, such as diet and oral hygiene measures, anti-microbial treatments and the provision of fluoride to the teeth.
  • Tooth sensitivity is also a common problem affecting children and adults.
  • tooth sensitivity may be caused by gingival recession, dentine exposure due to erosion or abrasion, or periodontal surgery that includes root planning. Such conditions leave the dentinal tubules of the tissue susceptible to irritation by chemical, bacterial, mechanical or thermal stimuli. Examples of stimuli include heat, cold, and sweet foods. It is believed that tooth sensitivity is the result of nerve endings of the dental pulp being excited by fluid flow through the exposed dentinal tubules.
  • Treatments directed to alleviating pain associated with sensitive teeth have generally focused on blocking access to the dentinal tubules so as to prevent stimuli from causing pain and sensitivity.
  • Many treatments have been developed which include application of inorganic or organic components designed to plug or otherwise block dentinal tubules for a limited time.
  • a disadvantage of such treatments is that normal habits such as eating certain foods (e.g., foods with a high acid content) or brushing can negate the treatment.
  • eating certain foods e.g., foods with a high acid content
  • brushing can negate the treatment.
  • Recently, testing has revealed that increased fluoride levels within the mouth may also be used as a treatment for tooth sensitivity (Toumba and Andreadis).
  • Arginine and other basic amino acids have been proposed for use in oral care and are believed to have significant benefits in combating cavity formation and tooth sensitivity. Combining these basic amino acids with minerals having oral care benefits, e.g., fluoride and calcium, to form an oral care product having acceptable long term stability, however, has proven challenging. Partly because of unaddressed formulation hurdles and partly because arginine has generally been viewed in the art as a potential alternative to fluoride rather than a co-active, there has been little motivation to make oral care products comprising both arginine and fluoride. Additional hurdles are potentially posed by addition of an antimicrobial agent. Commercially available arginine-based toothpaste, such as ProClude® and DenClude®, for example, contain arginine bicarbonate and calcium carbonate, but not fluoride nor any antimicrobial agent.
  • the invention provides a dental sealant composition comprising a basic amino acid in free or salt form (BAA).
  • the sealant composition additionally may comprise fluoride.
  • the BAA is preferably arginine, in free or orally acceptable salt form.
  • the present invention relates to a method of treating sensitive teeth with a basic amino acid in free or salt form (BAA) in a sealant composition, preferably in the presence of fluoride. The method involves: (1) attaching a BAA-releasing sealant composition to a person's tooth; and (2) allowing a BAA to be slowly released over time in order to reduce chronic and/or acute tooth sensitivity.
  • the sealant acts also as a fluoride releasing composition as well. Because the method relies on release of a BAA into the oral cavity, the method also prevents future pain associated with dental caries by preventing deminerahzation and maintaining strong enamel.
  • the invention further provides methods to improve oral health comprising use of a dental sealant composition comprising a BAA, e.g., by a subject in need thereof, to a. reduce or inhibit formation of dental caries, b. reduce, repair or inhibit early enamel lesions, c. reduce or inhibit demineraiization and promote reminera ⁇ zation of the teeth, d. reduce hypersensitivity of the teeth, e. reduce or inhibit gingivitis, f promote healing of sores or cuts in the mouth, g. reduce levels of acid producing bacteria, h. to increase relative levels of arginolytic bacteria. i. inhibit microbial biofilm formation in the oral cavity, j. raise and/or maintain plaque pH at levels of at least pH 5.5 following sugar challenge, k. reduce plaque accumulation,
  • the invention further provides the use of a BAA in the manufacture of a dental sealant, e.g., for use in a method of treating sensitive teeth, or in any of the methods set forth above.
  • the sealant compositions may be used for alleviating pain and/or sensitivity of teeth in addition to any effect that the BAA releasing sealant compositions may have in preventing dental caries.
  • the compositions may be attached to a tooth to provide slow-BAA releasing devices for releasing a BAA into the saliva of an individual.
  • the daily dissolution rate (DDR) of the composition under conditions in the mouth may range from about O.I to about 100 % per day.
  • the required DDR of the sealant composition will depend upon the duration of BAA release required. For example, if the composition is required to release a BAA over a long period, such as 1-2 years, the DDR is preferably about 0.1 to about 0.5 %. However, if a BAA need only be released for a shorter period, such as a few hours, days, weeks, or months, a faster releasing sealant may be used, for example having a DDR of up to about 100 %.
  • compositions which attaches to the teeth.
  • the compositions may be applied as a spray, for example using a hydrocarbon propellant.
  • the compositions comprise a polymer or vamish suitable for painting onto teeth,
  • the compositions may be incorporated into dental cement or filling materials.
  • the compositions may be attached to a tooth, for example being attached to rear molar using standard dental cement or as a powder for adding to dental materials, such as dental amalgams, thereby providing means to supplement a BAA release into saliva to assist in the prevention or reduction of dental caries.
  • the powder may be included in a number of other dental materials, such as fissure sealant resins or composite bonding materials to cement bonds and brackets in orthodontic appliances. Powder applications may use sealant compositions that have a lower DDR than those that are attached directly to a tooth, for example having a DDR of about 0.1 to about 1 %.
  • the inventive method involves attaching a BAA releasing sealant composition to a person's tooth, or a dental appliance, such as a denture, and then allowing a BAA to be slowly released over time in order to reduce chronic and/or acute tooth sensitivity.
  • the BAA releasing sealant composition comprises about 5 to about 75 weight percent BAA and about 5 to about 30 weight percent fluorine.
  • the basic amino acids which can be used in the compositions and methods of the invention include not only naturally occurring basic amino acids, such as arginine, lysine, and histidine, but also any basic amino acids having a carboxyl group and an amino group in the molecule, which are water-soluble and provide an aqueous solution with a pH of 7 or greater.
  • basic amino acids include, but are not limited to, arginine, lysine, citrullene, ornithine, creatine, histidine, diaminobutanoic acid, diaminoproprionic acid, salts thereof or combinations thereof.
  • the basic amino acids are selected from arginine, citrullene, and ornithine.
  • the basic amino acid is arginine, for example, 1-arginine, or a salt thereof, for example arginine bicarbonate, arginine phosphate, or arginine hydrochloride.
  • compositions of the invention are intended for consumption and so salts for use in the present invention should be safe for such use, in the amounts and concentrations provided.
  • Suitable salts include salts known in the art to be pharmaceutically acceptable salts are generally considered to be physiologically acceptable in the amounts and concentrations provided.
  • Physiologically acceptable salts include those derived from pharmaceutically acceptable inorganic or organic acids or bases, for example acid addition salts formed by acids which form a physiological acceptable anion, e.g., hydrochloride or bromide salt, and base addition salts formed by bases which form a physiologically acceptable cation, for example those derived from alkali metals such as potassium and sodium or alkaline earth metals such as calcium and magnesium.
  • Physiologically acceptable sails may be obtained using standard procedures known in the art, for example, by reacting a sufficiently basic compound such as an amine with a suitable acid affording a physiologically acceptable anion.
  • the concentration of BAA will vary depending on the formulation.
  • the BAA (amount of salt expressed as weight of the free base) is 1 - 40 % by weight of the formulation, e.g. 5 - 20%, for example about 10%.
  • compositions of the invention may additionally comprise tluoride.
  • Representative fluoride ion sources include, but are not limited to, stannous fluoride, sodium fluoride, potassium fluoride, sodium monofluorophosphate, sodium fluorosilicate, ammonium fluorosilicate. amine fluoride, ammonium fluoride, and combinations thereof.
  • the fluoride ion source includes stannous fluoride, sodium fluoride, sodium monofluorophosphate as well as mixtures thereof.
  • the fluoride source is sodium fluoride or sodium monofluorophosphate.
  • the fluoride may be present in the formulation in effective amounts, as used i ⁇ conventional dental sealants, e.g.
  • the composition may, for example be present, e.g., in an amount of about 2,500 ppm to about 250,000 ppm, expressed as level of fluoride ion, or in an amount of 2 - 25%, for example, at least 12%, e.g., 15 - 25% by weight of the composition.
  • compositions may additionally comprise an antibacterial agent, such as iriclosan, or an agent which inhibits attachment of bacteria.
  • an antibacterial agent such as iriclosan, or an agent which inhibits attachment of bacteria.
  • J0027J Formulations comprising 30 wt % arginine bicarbonate are prepared as follows: TABLE 1
  • Varnish formulation comprising 10 wt % arginine hydrochloride is prepared as follows:

Abstract

The invention provides a method of treating sensitive teeth comprising attaching a sealant composition comprising a basic amino acid to a person's tooth and allowing the basic amino acid to be slowly released over time in order to reduce chrome and/or acute tooth sensitivity together with compositions and methods of use.

Description

TOOTH SEALANT
[O0Θ1J This application claims the benefit of U.S. Ser. No. 61/027,425 filed February 8, 2008, the contents of which are incorporated herein by reference.
FIELD OF THE INVENTION
[0002] The present invention relates to tooth sealant compositions comprising a basic amino acid in free or salt form that may be used to help prevent demineralization of teeth, alleviate pain and/or sensitivity of a patient's teeth, and provide other benefits. Sealants may include polymeric coatings, varnishes and foams to coat the teeth and/or dental device for extended periods.
BACKGROUND
[0003] Dental caries consist of demineralization of a tooth caused by bacteria. In the early stages of caries a white spot develops on the tooth and if the disease is not halted and reversed, the enamel surface breaks down to form a lesion. This can then lead to decay and eventually, a fractured tooth. It is well known that development of dental caries may be reduced by means of various factors, such as diet and oral hygiene measures, anti-microbial treatments and the provision of fluoride to the teeth.
[0004) Tooth sensitivity is also a common problem affecting children and adults. Generally, tooth sensitivity may be caused by gingival recession, dentine exposure due to erosion or abrasion, or periodontal surgery that includes root planning. Such conditions leave the dentinal tubules of the tissue susceptible to irritation by chemical, bacterial, mechanical or thermal stimuli. Examples of stimuli include heat, cold, and sweet foods. It is believed that tooth sensitivity is the result of nerve endings of the dental pulp being excited by fluid flow through the exposed dentinal tubules.
[0005] Treatments directed to alleviating pain associated with sensitive teeth have generally focused on blocking access to the dentinal tubules so as to prevent stimuli from causing pain and sensitivity. Many treatments have been developed which include application of inorganic or organic components designed to plug or otherwise block dentinal tubules for a limited time. A disadvantage of such treatments is that normal habits such as eating certain foods (e.g., foods with a high acid content) or brushing can negate the treatment. Recently, testing has revealed that increased fluoride levels within the mouth may also be used as a treatment for tooth sensitivity (Toumba and Andreadis). [0006] Current methods for administering fluoride for caries prevention include the fluoridation of drinking water, the ingestion of fluoride tablets, the incorporation of fluoride into mouth washes, toothpastes, and foods, the topical application of fluoride solutions, gels and varnishes and recently, the incorporation of fluoride in dental materials and devices. [00Θ7J Evidence supports the concept of frequent applications of relatively low concentrations of fluoride ions for the prevention of caries and the treatment of sensitive teeth. A sustained and controlled release delivery system could help to achieve this goal.
[0008] Arginine and other basic amino acids have been proposed for use in oral care and are believed to have significant benefits in combating cavity formation and tooth sensitivity. Combining these basic amino acids with minerals having oral care benefits, e.g., fluoride and calcium, to form an oral care product having acceptable long term stability, however, has proven challenging. Partly because of unaddressed formulation hurdles and partly because arginine has generally been viewed in the art as a potential alternative to fluoride rather than a co-active, there has been little motivation to make oral care products comprising both arginine and fluoride. Additional hurdles are potentially posed by addition of an antimicrobial agent. Commercially available arginine-based toothpaste, such as ProClude® and DenClude®, for example, contain arginine bicarbonate and calcium carbonate, but not fluoride nor any antimicrobial agent.
BRIEF SUMMARY OF THE INVENTION
[0009} In one embodiment, the invention provides a dental sealant composition comprising a basic amino acid in free or salt form (BAA). The sealant composition additionally may comprise fluoride. The BAA is preferably arginine, in free or orally acceptable salt form. 10010] In another embodiment, the present invention relates to a method of treating sensitive teeth with a basic amino acid in free or salt form (BAA) in a sealant composition, preferably in the presence of fluoride. The method involves: (1) attaching a BAA-releasing sealant composition to a person's tooth; and (2) allowing a BAA to be slowly released over time in order to reduce chronic and/or acute tooth sensitivity. Preferably, the sealant acts also as a fluoride releasing composition as well. Because the method relies on release of a BAA into the oral cavity, the method also prevents future pain associated with dental caries by preventing deminerahzation and maintaining strong enamel.
[0011 j The invention further provides methods to improve oral health comprising use of a dental sealant composition comprising a BAA, e.g., by a subject in need thereof, to a. reduce or inhibit formation of dental caries, b. reduce, repair or inhibit early enamel lesions, c. reduce or inhibit demineraiization and promote remineraϋzation of the teeth, d. reduce hypersensitivity of the teeth, e. reduce or inhibit gingivitis, f promote healing of sores or cuts in the mouth, g. reduce levels of acid producing bacteria, h. to increase relative levels of arginolytic bacteria. i. inhibit microbial biofilm formation in the oral cavity, j. raise and/or maintain plaque pH at levels of at least pH 5.5 following sugar challenge, k. reduce plaque accumulation,
1. treat dry mouth, m. whiten teeth, n. enhance systemic health, including cardiovascular health, e.g., by reducing potential for systemic infection via the oral tissues, o. reduce erosion of the teeth, p. immunize the teeth against cariogenic bacteria, and/or q. clean the teeth and oral cavity.
[0012] The invention further provides the use of a BAA in the manufacture of a dental sealant, e.g., for use in a method of treating sensitive teeth, or in any of the methods set forth above. [0013] The sealant compositions may be used for alleviating pain and/or sensitivity of teeth in addition to any effect that the BAA releasing sealant compositions may have in preventing dental caries. The compositions may be attached to a tooth to provide slow-BAA releasing devices for releasing a BAA into the saliva of an individual.
(0014| The daily dissolution rate (DDR) of the composition under conditions in the mouth may range from about O.I to about 100 % per day. The required DDR of the sealant composition will depend upon the duration of BAA release required. For example, if the composition is required to release a BAA over a long period, such as 1-2 years, the DDR is preferably about 0.1 to about 0.5 %. However, if a BAA need only be released for a shorter period, such as a few hours, days, weeks, or months, a faster releasing sealant may be used, for example having a DDR of up to about 100 %.
By "dental sealant composition" is meant a composition which attaches to the teeth. The compositions may be applied as a spray, for example using a hydrocarbon propellant. Alternatively, the compositions comprise a polymer or vamish suitable for painting onto teeth, Alternatively, the compositions may be incorporated into dental cement or filling materials. For example, the compositions may be attached to a tooth, for example being attached to rear molar using standard dental cement or as a powder for adding to dental materials, such as dental amalgams, thereby providing means to supplement a BAA release into saliva to assist in the prevention or reduction of dental caries. The powder may be included in a number of other dental materials, such as fissure sealant resins or composite bonding materials to cement bonds and brackets in orthodontic appliances. Powder applications may use sealant compositions that have a lower DDR than those that are attached directly to a tooth, for example having a DDR of about 0.1 to about 1 %.
[0015] These and other benefits, advantages and features of the present invention will become more full apparent from the following description and appended claims, or may be learned by the practice of the invention as set forth hereinafter.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS [0016] The inventive method involves attaching a BAA releasing sealant composition to a person's tooth, or a dental appliance, such as a denture, and then allowing a BAA to be slowly released over time in order to reduce chronic and/or acute tooth sensitivity. According to a preferred embodiment, the BAA releasing sealant composition comprises about 5 to about 75 weight percent BAA and about 5 to about 30 weight percent fluorine.
[0017] Slow-release BAA devices consistently raise intra-oral salivary BAA levels for periods up to 2 years or more, and now also appear to completely alleviate the symptoms of dentine sensitivity within two weeks, while maintaining the benefit for up to six months or more in adults. Subjects report complete alleviation of their dentine sensitivity. There are no adverse events reported or observed. There is a slight tendency for an increase in plaque and gingival indices, but this is non-significant.
(0018 j The basic amino acids which can be used in the compositions and methods of the invention include not only naturally occurring basic amino acids, such as arginine, lysine, and histidine, but also any basic amino acids having a carboxyl group and an amino group in the molecule, which are water-soluble and provide an aqueous solution with a pH of 7 or greater.
(0019) Accordingly, basic amino acids include, but are not limited to, arginine, lysine, citrullene, ornithine, creatine, histidine, diaminobutanoic acid, diaminoproprionic acid, salts thereof or combinations thereof. In a particular embodiment, the basic amino acids are selected from arginine, citrullene, and ornithine.
(0020] In certain embodiments, the basic amino acid is arginine, for example, 1-arginine, or a salt thereof, for example arginine bicarbonate, arginine phosphate, or arginine hydrochloride.
[0021] The compositions of the invention are intended for consumption and so salts for use in the present invention should be safe for such use, in the amounts and concentrations provided. Suitable salts include salts known in the art to be pharmaceutically acceptable salts are generally considered to be physiologically acceptable in the amounts and concentrations provided. Physiologically acceptable salts include those derived from pharmaceutically acceptable inorganic or organic acids or bases, for example acid addition salts formed by acids which form a physiological acceptable anion, e.g., hydrochloride or bromide salt, and base addition salts formed by bases which form a physiologically acceptable cation, for example those derived from alkali metals such as potassium and sodium or alkaline earth metals such as calcium and magnesium. Physiologically acceptable sails may be obtained using standard procedures known in the art, for example, by reacting a sufficiently basic compound such as an amine with a suitable acid affording a physiologically acceptable anion.
[0022] The concentration of BAA will vary depending on the formulation. In one embodiment, the BAA (amount of salt expressed as weight of the free base) is 1 - 40 % by weight of the formulation, e.g. 5 - 20%, for example about 10%.
(0023] The compositions of the invention may additionally comprise tluoride. Representative fluoride ion sources include, but are not limited to, stannous fluoride, sodium fluoride, potassium fluoride, sodium monofluorophosphate, sodium fluorosilicate, ammonium fluorosilicate. amine fluoride, ammonium fluoride, and combinations thereof. In certain embodiments the fluoride ion source includes stannous fluoride, sodium fluoride, sodium monofluorophosphate as well as mixtures thereof. In a particular embodiment, the fluoride source is sodium fluoride or sodium monofluorophosphate. The fluoride may be present in the formulation in effective amounts, as used iα conventional dental sealants, e.g. higher than typically used in toothpaste. It may, for example be present, e.g., in an amount of about 2,500 ppm to about 250,000 ppm, expressed as level of fluoride ion, or in an amount of 2 - 25%, for example, at least 12%, e.g., 15 - 25% by weight of the composition.
[0024] The compositions may additionally comprise an antibacterial agent, such as iriclosan, or an agent which inhibits attachment of bacteria.
[0025] As used throughout, ranges are used as shorthand for describing each and every value that is within the range. Any value within the range can be selected as the terminus of the range. In addition, all references cited herein are hereby incorporated by reference in their entireties, In the event of a conflict in a definition in the present disclosure and that of a cited reference, the present disclosure controls. It is understood that when formulations are described, they may be described in terms of their ingredients, as is common in the art, notwithstanding that these ingredients may react with one another in the actual formulation as it is made, stored and used, and such products are intended to be covered by the formulations described. [0026] The following examples further describe and demonstrate illustrative embodiments within the scope of the present invention. The examples are given solely for illustration and are not to be construed as limitations of this invention as many variations are possible without departing from (he spirit and scope thereof. Various modifications of the invention in addition to those shown and described herein should be apparent to those skilled in the art and are intended to fall within the appended claims. EXAMPLES Example 1
J0027J Formulations comprising 30 wt % arginine bicarbonate are prepared as follows: TABLE 1
Ingredient (Part 1) %
Water QS
Sodium Fluoride 2.65
Malic Acid 1,75
Sodium Mono phosphate 1.38 Sodium Methyl Coeoyi Taurate 1
Flavor 0.6
Sodium Saccharin 0.35 Sodium Benzoate 0.1
Arginine Bicarbonate 10
Total (Part i) 100
Part 2
Part 1 93
Hydrocarbon propellant mixture 7
Total 100
Example 2
[0028} Varnish formulation comprising 10 wt % arginine hydrochloride is prepared as follows:
TABLE 2
Ingredient %
Colophoniυm 22.01
90% Ethyl Alcohol 27.87
Shellac 21.5
Mastic 11.82
Sodium Fluoride 4.98
Sodium Saccharin 0.68
Raspberry Flavor 0.65
White Beeswax 0.48
Arginine Hydrochloride 10
Total 100

Claims

1. A method of treating sensitive teeth comprising: attaching a sealent composition comprising a basic amino acid in free or salt form (BAA) to a tooth of a person in need thereof; and allowing BAA to be slowly released over time in order to reduce chronic and/or acute tooth sensitivity.
2. The method as recited in claim 1, wherein the composition additionally comprises fluoride.
3. The method as recited in claim 2, wherein fluoride is slowly released over time,
4. The method as recited in claim 3, wherein the fluoride ions are included in compounds selected from the group consisting of aluminum fluoride, sodium hydrogen fluoride, sodium fluoride, calcium fluoride, magnesium fluoride, and potassium fluoride.
5. The method as recited in claim 2, wherein at least about 12 weight percent of fluoride is included in the composition.
6. The method as recited in claim 2, wherein about 15 to about 25 weight percent fluoride is included in the composition.
7. The method as recited in claim 2, wherein the composition has a DDR in the range of about 0.1 to about 100 %.
8. The method as recited in claim 2, wherein the composition has a DDR in the range of about 0.1 to about 0.5 %.
9. The method as recited in claim 2, wherein the composition is provided in powder form.
10. The method as recited in claim 9, wherein the powder form of the sealant composition comprises powder grains having a grain size of less than about 38 microns.
11. The method as recited in claim 10, wherein the powder form of the sealant composition comprises powder grains having a grain size of less than about 106 microns.
12. The method as recited in claim 10, wherein the powdered composition is incorporated in one or more dental materials,
13. The method as recited in claim 12, wherein the dental material is selected from the group consisting of a dental amalgam, a fissure sealant resin, a composite bonding material, an orthodontic appliance, a dental prosthetic, a resin varnish, and an oral surgery implant. The method as recited in claim 2, wherein the composition comprises at least one pellet that may be attached to a tooth using dental cement, wherein said at least one pellet comprises BAA. A dental sealant composition comprising a basic amino acid in free or salt form (BAA). The sealant composition of claim 15 which additionally comprises fluoride. The sealant composition of claim 15 or 16 wherein the BAA comprises arginine, in free or salt form. The sealant composition of any of claims 15 ■■■ 17 comprising aluminum fluoride, sodium hydrogen fluoride, sodium fluoride, calcium fluoride, magnesium fluoride, or potassium fluoride. The sealant composition of any of claims 15 - 18 wherein at least about 12 weight percent of fluoride is included in the composition. The sealant composition of any of claims 15 - 39, wherein the composition has a DDR in the range of about 0.1 to about 100 %. The sealant composition of claim 20, wherein the composition has a DDR in the range of about 0.1 to about 0.5 %. The sealant composition of any of claims 15 - 21, wherein the composition is provided in powder form. The sealant composition of any of claims 15 - 22, incorporated into a dental material selected from the group consisting of a dental amalgam, a fissure sealant resin, a composite bonding material, an orthodontic appliance, a dental prosthetic, a resin varnish, and an oral surgery implant. The use of a basic amino acid in free or salt form in the manufacture of a dental sealant composition.
PCT/US2009/033312 2008-02-08 2009-02-06 Tooth sealant WO2009100283A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
EP09708758.9A EP2249764B1 (en) 2008-02-08 2009-02-06 Tooth sealant
JP2010544489A JP2011510095A (en) 2008-02-08 2009-02-06 Dental Sealant [0001] This application claims the benefit of US Serial No. 61 / 027,425, filed February 8, 2008, the contents of which are incorporated herein by reference.
BRPI0907103A BRPI0907103A2 (en) 2008-02-08 2009-02-06 A method for treating sensitive teeth, making dental sealants, and using a basic free-form or salt-based amino acid.
CA2711262A CA2711262C (en) 2008-02-08 2009-02-06 Dental composition comprising a basic amino acid for alleviating tooth sensitivity
CN2009801045327A CN101938970A (en) 2008-02-08 2009-02-06 Tooth sealant
US12/866,766 US10391038B2 (en) 2008-02-08 2009-02-06 Tooth sealant
RU2010137322/15A RU2493812C2 (en) 2008-02-08 2009-02-06 Dental seal
AU2009212339A AU2009212339B2 (en) 2008-02-08 2009-02-06 Tooth sealant
MX2010007738A MX2010007738A (en) 2008-02-08 2009-02-06 Tooth sealant.
ZA2010/03694A ZA201003694B (en) 2008-02-08 2010-05-24 Tooth sealant

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2742508P 2008-02-08 2008-02-08
US61/027,425 2008-02-08

Publications (2)

Publication Number Publication Date
WO2009100283A2 true WO2009100283A2 (en) 2009-08-13
WO2009100283A3 WO2009100283A3 (en) 2009-11-12

Family

ID=40952706

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/033312 WO2009100283A2 (en) 2008-02-08 2009-02-06 Tooth sealant

Country Status (14)

Country Link
US (1) US10391038B2 (en)
EP (1) EP2249764B1 (en)
JP (2) JP2011510095A (en)
CN (1) CN101938970A (en)
AR (1) AR070589A1 (en)
AU (1) AU2009212339B2 (en)
BR (1) BRPI0907103A2 (en)
CA (1) CA2711262C (en)
CO (1) CO6241091A2 (en)
MX (1) MX2010007738A (en)
RU (1) RU2493812C2 (en)
TW (1) TWI376237B (en)
WO (1) WO2009100283A2 (en)
ZA (1) ZA201003694B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016101158A1 (en) * 2014-12-24 2016-06-30 Colgate-Palmolive Company Oral care composition
US11260103B2 (en) 2014-12-29 2022-03-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for delivering lypophilic agents to dental pulp and for enhancing dentin production

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102406403A (en) * 2011-12-19 2012-04-11 吴江市江南不锈钢器材有限责任公司 Cup casing
US9107838B2 (en) 2012-04-25 2015-08-18 Therametrics Technologies, Inc. Fluoride varnish
EP2705825B1 (en) * 2012-09-07 2018-10-31 Ivoclar Vivadent AG Varnish containing fluoride for application to the surface of teeth
WO2014127178A1 (en) * 2013-02-15 2014-08-21 Dentsply International Inc. Dental varnish compositions
CN104758311A (en) * 2015-04-24 2015-07-08 杭州维瓦科技有限公司 Compound for treating hemodia and preparation method thereof
US20180243175A1 (en) * 2015-09-10 2018-08-30 The University Of Florida Research Foundation, Inc. Arginine-containing restorative dental materials and methods of preventing and controlling caries associated with dental work
CN106361579A (en) * 2016-11-10 2017-02-01 李雨阳 Production method of tooth surface self-cleaning anti-adhesion coating

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3943241A (en) * 1971-08-30 1976-03-09 General Mills, Inc. Cariostatic composition
US3932608A (en) * 1971-08-30 1976-01-13 General Mills, Inc. Food composition
US3932605A (en) * 1972-06-12 1976-01-13 Jaroslav Vit Dental treatment
US3988434A (en) * 1972-08-07 1976-10-26 Schole Murray L Dental preparation
US4025616A (en) * 1973-03-06 1977-05-24 The Procter & Gamble Company Oral compositions for plaque, caries and calculus retardation with reduced staining tendencies
US4100269A (en) * 1973-06-28 1978-07-11 Lever Brothers Company Anticalculus dentifrice
US4022880A (en) * 1973-09-26 1977-05-10 Lever Brothers Company Anticalculus composition
US3925543A (en) * 1973-11-01 1975-12-09 Colgate Palmolive Co Antibacterial oral compositions containing preservative-antioxidants
US4011309A (en) * 1975-01-20 1977-03-08 Marion Laboratories, Inc. Dentifrice composition and method for desensitizing sensitive teeth
US3954457A (en) * 1975-04-28 1976-05-04 Gary Maurice Weikel Dental amalgam
US4064138A (en) * 1975-11-12 1977-12-20 General Mills, Inc. Amino acid derivatives
ZA773318B (en) * 1976-06-18 1978-04-26 I Kleinberg Means and method for improving natural defenses against caries
USRE31181E (en) * 1976-06-18 1983-03-15 Means and method for improving natural defenses against caries
US4108981A (en) * 1976-08-02 1978-08-22 Indiana University Foundation Alkaline oral compositions comprising aluminum and a carboxylic acid
US4108979A (en) * 1976-08-02 1978-08-22 Indiana University Foundation Dentifrice preparations comprising aluminum and a compatible abrasive
US4042680A (en) * 1976-08-02 1977-08-16 Indiana University Foundation Anticariogenic maloaluminate complexes
JPS5367290A (en) * 1976-11-16 1978-06-15 Sankin Ind Co Hydraulic cement for dental treatment
US4146607A (en) * 1977-11-07 1979-03-27 Lever Brothers Company Synergistic anti-plaque mixture with tetradecylamine plus aluminum and/or zinc
US4160821A (en) * 1978-02-27 1979-07-10 Johnson & Johnson Treatment for gingivitis
US4213961A (en) 1978-03-23 1980-07-22 Beecham, Inc. Oral compositions
GB1573727A (en) * 1978-05-19 1980-08-28 Colgate Palmolive Co Dentifrices
US4216961A (en) * 1978-08-04 1980-08-12 Mcquillan Mary J Table baseball apparatus
JPS5569549A (en) * 1978-11-16 1980-05-26 Nitto Boseki Co Ltd Novel substrate for determination of enzyme activity
US4225579A (en) * 1979-02-27 1980-09-30 Israel Kleinberg Means and method for improving defenses against caries
US4339432A (en) * 1979-06-20 1982-07-13 Lever Brothers Company Oral mouthwash containing zinc and glycine
US4269822A (en) * 1979-07-20 1981-05-26 Laclede Professional Products, Inc. Antiseptic dentifrice
JPS5846483B2 (en) * 1979-09-20 1983-10-17 ライオン株式会社 Oral composition
JPS5835965B2 (en) * 1979-07-31 1983-08-05 ライオン株式会社 Oral composition
JPS5924129B2 (en) * 1980-12-11 1984-06-07 三金工業株式会社 dental cement adhesive
US4532124A (en) * 1981-08-19 1985-07-30 Development Finance Corporation Of New Zealand Dental rinse
JPS58118509A (en) * 1981-12-29 1983-07-14 Lion Corp Composition for oral cavity
US4885155A (en) * 1982-06-22 1989-12-05 The Procter & Gamble Company Anticalculus compositions using pyrophosphate salt
US4477429A (en) * 1982-08-26 1984-10-16 Johnson & Johnson Products, Inc. Oral compositions comprising N.sup.α -alkyl derivatives of arginine
US4499067A (en) * 1982-08-26 1985-02-12 Johnson & Johnson Products, Inc. Oral compositions comprising NG -acyl derivatives of arginine
US4725576A (en) * 1983-12-29 1988-02-16 Research Foundation Of State University Of New York Fungicidal polypeptide compositions containing L-histidine and methods for use therefore
US4528181A (en) 1984-02-01 1985-07-09 Colgate-Palmolive Company Dentifrice containing dual sources of fluoride
US5334617A (en) * 1984-03-19 1994-08-02 The Rockefeller University Amino acids useful as inhibitors of the advanced glycosylation of proteins
GB8411731D0 (en) * 1984-05-09 1984-06-13 Unilever Plc Oral compositions
JPH0742219B2 (en) * 1984-07-26 1995-05-10 ライオン株式会社 Oral composition
US4538990A (en) * 1984-09-24 1985-09-03 Medical College Of Ga. Research Institute, Inc. Method of decreasing the permeability of a dental cavity
US4738722A (en) * 1986-09-15 1988-04-19 Den-Mat Corporation Dental compositions incorporating glass ionomers
JPH01139524A (en) * 1987-11-25 1989-06-01 Shiseido Co Ltd Composition for oral cavity
US5174989A (en) 1987-11-25 1992-12-29 Shiseido Company Ltd. Oral composition
GB8729564D0 (en) * 1987-12-18 1988-02-03 Unilever Plc Oral compositions
US5438076A (en) 1988-05-03 1995-08-01 Perio Products, Ltd. Liquid polymer composition, and method of use
JP2630640B2 (en) * 1988-11-15 1997-07-16 宇部興産株式会社 Calcium phosphate cement pit fissure cold material
US5139768A (en) 1989-01-31 1992-08-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Dental composition for hypersensitive teeth
US5096700A (en) * 1990-09-28 1992-03-17 The Procter & Gamble Company Halogenated aminohexanoates and aminobutyrates antimicrobial agents
DE4110796A1 (en) * 1991-04-04 1992-10-08 Bayer Ag PROVISIONAL FASTENING MATERIALS
US5370865A (en) * 1992-05-15 1994-12-06 Kao Corporation Composition for use in oral cavity
US5286480A (en) * 1992-06-29 1994-02-15 The Procter & Gamble Company Use of N-acetylated amino acid complexes in oral care compositions
US5369142A (en) * 1993-01-15 1994-11-29 The Ohio State University Water soluble polymers containing amino acid residues for dental restoratives
US5505933A (en) * 1994-06-27 1996-04-09 Colgate Palmolive Company Desensitizing anti-tartar dentifrice
EP0704533A1 (en) * 1994-09-30 1996-04-03 Bayer Ag An attenuated vaccination virus, a method to make the virus and a pharmaceutical compositions comprising the virus
DE4445266A1 (en) * 1994-12-19 1996-06-20 Thera Ges Fuer Patente Fluoride-releasing composite materials
DE69618786T2 (en) * 1995-07-10 2002-11-07 Unilever Nv HEAT GENERATING TOOTHPASTE
US5747005A (en) 1995-08-02 1998-05-05 Barels; Ronald R. Oil-based, anti-plaque dentifrice composition
US6036944A (en) 1995-08-08 2000-03-14 Enamelon, Inc. Processes for the remineralization and mineralization of teeth
JPH0958053A (en) 1995-08-29 1997-03-04 Ricoh Co Ltd Image forming apparatus
CA2184802C (en) * 1995-10-10 2007-07-31 Karl-Heinz Bender Process for manufacture of imidazo benzodiazepine derivatives
US5895788A (en) * 1996-01-31 1999-04-20 The Board Of Trustees Of The University Of Arkansas Use of L-arginine and salts thereof in drinking water for the prevention and/or treatment of pulmonary hypertension syndrome in avians
US5762911A (en) * 1996-03-05 1998-06-09 The Research Foundation Of State University Of New York Anti-caries oral compositions
US6488961B1 (en) * 1996-09-20 2002-12-03 Ethypharm, Inc. Effervescent granules and methods for their preparation
US5906811A (en) * 1997-06-27 1999-05-25 Thione International, Inc. Intra-oral antioxidant preparations
FR2768624B1 (en) * 1997-09-25 1999-11-12 Oreal USE OF AN EXCITING AMINO ACID INHIBITOR IN A COSMETIC OR DERMATOLOGICAL COMPOSITION FOR SENSITIVE SKIN AND COMPOSITION OBTAINED
US5922346A (en) * 1997-12-01 1999-07-13 Thione International, Inc. Antioxidant preparation
US6805883B2 (en) * 1998-03-12 2004-10-19 Mars, Incorporated Food products containing polyphenol(s) and L-arginine to stimulate nitric oxide
JP2000044422A (en) * 1998-07-31 2000-02-15 Hironori Oka Coating composition for tooth and its production
US5997301A (en) * 1998-10-20 1999-12-07 Linden; Lars Ake Treatment of tooth surfaces and substances therefor
US6166102A (en) * 1998-12-08 2000-12-26 Block Drug Company, Inc. Denture adhesive
US6436370B1 (en) * 1999-06-23 2002-08-20 The Research Foundation Of State University Of New York Dental anti-hypersensitivity composition and method
GB2354441A (en) 1999-08-06 2001-03-28 Mccormack Ltd Composition for treating dentine hypersensitivity
US7323160B2 (en) * 1999-08-14 2008-01-29 Teldent Ltd. Method of treating a patient's teeth using fluoride releasing glass composition
IL135061A0 (en) 2000-03-14 2001-05-20 Ahron Jodaikin Strategic targeted fluoridation and chemical treatment of teeth
WO2001076549A2 (en) * 2000-04-11 2001-10-18 Gerald Mc Laughlin Composition and method for whitening teeth
JP2002097125A (en) * 2000-09-21 2002-04-02 Hironori Oka Teeth bleaching composition keeping natural teeth color
US20020081360A1 (en) * 2000-12-27 2002-06-27 Andreas Burgard Salts of L-amino acid having improved taste and their preparation
RU2238078C1 (en) * 2003-01-21 2004-10-20 Чухаджян Ара Гарникович Therapeutic and prophylactic topical-destination facility in the form of self-sticking film for remineralization of solid dental tissues
JP2005015435A (en) 2003-06-27 2005-01-20 Sun Medical Co Ltd Polymerizable composition and its polymer
US20050175552A1 (en) 2004-02-10 2005-08-11 Hoic Diego A. Tooth coating compositions and methods therefor
ATE374583T1 (en) * 2004-03-05 2007-10-15 Straumann Holding Ag PROCESS OF MANUFACTURING A DENTAL DEVICE USING INJECTION MOLDING
US20090068123A1 (en) * 2005-03-30 2009-03-12 Kuraray Medical Inc Fluorine ion-releasable composition for dental purposes
MX348545B (en) * 2005-07-12 2017-06-16 Colgate-Palmolive Company * Oral care implement having reservoir for dispensing active agent.
US20070238808A1 (en) * 2006-03-09 2007-10-11 Goldberg A J Dental materials, methods of making and using the same, and articles formed therefrom
US8501161B2 (en) * 2006-05-09 2013-08-06 Colgate-Palmolive Company Oral care regimen
US8900558B2 (en) * 2006-06-30 2014-12-02 Colgate-Palmolive Company High fluoride ion oral care composition and method for maintaining anticaries activity
AR072341A1 (en) 2008-02-08 2010-08-25 Colgate Palmolive Co METHODS FOR THE PRODUCTION OF ARGININE BICARBONATE

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None
See also references of EP2249764A4

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016101158A1 (en) * 2014-12-24 2016-06-30 Colgate-Palmolive Company Oral care composition
US11260103B2 (en) 2014-12-29 2022-03-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for delivering lypophilic agents to dental pulp and for enhancing dentin production

Also Published As

Publication number Publication date
BRPI0907103A2 (en) 2016-05-03
AU2009212339B2 (en) 2011-12-22
RU2493812C2 (en) 2013-09-27
AR070589A1 (en) 2010-04-21
MX2010007738A (en) 2010-08-10
EP2249764A4 (en) 2012-02-22
CN101938970A (en) 2011-01-05
TW201000143A (en) 2010-01-01
CA2711262A1 (en) 2009-08-13
RU2010137322A (en) 2012-03-20
ZA201003694B (en) 2014-11-26
US20100316726A1 (en) 2010-12-16
US10391038B2 (en) 2019-08-27
JP2011510095A (en) 2011-03-31
EP2249764B1 (en) 2019-07-31
CO6241091A2 (en) 2011-01-20
TWI376237B (en) 2012-11-11
EP2249764A2 (en) 2010-11-17
JP2014088419A (en) 2014-05-15
CA2711262C (en) 2015-06-23
WO2009100283A3 (en) 2009-11-12
AU2009212339A1 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
US10391038B2 (en) Tooth sealant
US5849266A (en) Dental composition for hypersensitive teeth
TW201215410A (en) Therapeutic oral compositions
RU2519329C2 (en) Compositions and devices
US8303938B2 (en) Anti-calculus dental composition
CN101938984A (en) Cleaning compositions and methods
EP0381445A2 (en) Dental composition for hypersensitive teeth
US11723847B2 (en) Dual component oral composition for enhancing remineralization of teeth
CN106413814A (en) Oral care compositions and methods
Coessens et al. Plaque-inhibiting effect of bioadhesive mucosal tablets containing chlorhexidine in a 4-day plaque regrowth model
Kumar et al. Advanced materials for prevention of calculus formation on enamel: A review
JPH11240816A (en) Composition for coating tooth
JP2005320321A (en) Dentifrice composition
Kaur et al. Neoteric Non-Fluoride Enamel Remineralization Systems: A Review
EP4044995A1 (en) Oral care composition
WO2007078074A1 (en) Mouthwash composition for the prevention of dental diseases
Sohi et al. Fresh Mouth is a Gateway to a Healthy Body–An Overview of Current Use of Chlorhexidine
US20070292368A1 (en) Oral care composition
Mason Dental and mouthwash preparations
HUE028801T2 (en) Anticaries compositions containing phaseolamin

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980104532.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09708758

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2009212339

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 12010501152

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 2009212339

Country of ref document: AU

Date of ref document: 20090206

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 3706/DELNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: PI 2010002110

Country of ref document: MY

WWE Wipo information: entry into national phase

Ref document number: 2711262

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/007738

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2010544489

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 12866766

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 10109377

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2009708758

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010137322

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0907103

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100727